The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Chemotherapy resistance in osteosarcoma: current challenges and future directions
Abstract
For patients with osteosarcoma, the use of chemotherapy has improved survival from 11% with surgical resection alone in the 1960s, to 70% by the mid-1980s. However, survival has since plateaued, despite advances in anticancer therapy. Elucidation of the mechanisms of chemoresistance and implementation of strategies to overcome chemoresistance will likely be pivotal to improving survival. In this review, the focus is on the current understanding of the mechanisms of resistance to the most commonly used agents in the treatment of osteosarcoma and the methods employed to overcome chemotherapy resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · cited 2×
“27 Gottesman MM. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615–627 (2002). • Provides a general framework for drug resistance in cancer.”
BackgroundA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751
Post-translational modification of p53 in tumorigenesis
Bode, A. M., & Dong, Z. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1455 · Cited by 1,270
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,204
The retinoblastoma tumour suppressor in development and cancer
Classon, M., & Harlow, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc950 · Cited by 738
Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D., Bernstein, M. L., Conrad, E., Ferguson, W., Gebhardt, M., Goorin, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.031 · Cited by 717
Biology and Therapeutic Advances for Pediatric Osteosarcoma
Marina, N., Gebhardt, M., Teot, L., & Gorlick, R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-422 · Cited by 671
Self-citationCommon Musculoskeletal Tumors of Childhood and Adolescence
Arndt, C. A. S., & Crist, W. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907293410507 · Cited by 657
Kempf-Bielack, B., Bielack, S. S., Jürgens, H., Branscheid, D., Berdel, W. E., Exner, G. U., Göbel, U., Helmke, K., Jundt, G., Kabisch, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.063 · Cited by 643
Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035153 · Cited by 623
Stem-Like Cells in Bone Sarcomas: Implications for Tumorigenesis
Gibbs, C. P., Kukekov, V. G., Reith, J. D., Tchigrinova, O., Suslov, O. N., Scott, E. W., Ghivizzani, S. C., Ignatova, T. N., & Steindler, D. A. (2005) · Neoplasia · doi:10.1593/neo.05394 · Cited by 492
Bacci, G., Ferrari, S., Bertoni, F., Ruggieri, P., Picci, P., Longhi, A., Casadei, R., Fabbri, N., Forni, C., Versari, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.24.4016 · Cited by 438
Ferrari, S., Smeland, S., Mercuri, M., Bertoni, F., Longhi, A., Ruggieri, P., Alvegard, T. A., Picci, P., Capanna, R., Bernini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.5785 · Cited by 435
Fuchs, N., Bielack, S. S., Epler, D., Bieling, P., Delling, G., Körholz, D., Graf, N., Heise, U., Jürgens, H., Kotz, R., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008391103132 · Cited by 343
Chen, Z., Lee, K., WALTHER, S. E., Raftogianis, R. B., Kuwano, M., Zeng, H., & Kruh, G. D. (2002) · PubMed · Cited by 316
Radiotherapy for local control of osteosarcoma
DeLaney, T. F., Park, L., Goldberg, S. I., Hug, E. B., Liebsch, N. J., Munzenrider, J. E., & Suit, H. D. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.05.051 · Cited by 306
Anticancer Antifolates: Current Status and Future Directions
McGuire, J. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033453712 · Cited by 305
Expression of HER2/erb B-2 Correlates With Survival in Osteosarcoma
Gorlick, R., Huvos, A. G., Heller, G., Aledo, A., Beardsley, G. P., Healey, J. H., & Meyers, P. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2781 · Cited by 303
Self-citationScotlandi, K., Manara, M. C., Nicoletti, G., Lollini, P.-L., Lukas, S., Benini, S., Croci, S., Perdichizzi, S., Zambelli, D., Serra, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3192 · Cited by 299
Sandberg, A. A., & Bridge, J. A. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00105-5 · Cited by 262
Hoang, B. H., Kubo, T., Healey, J. H., Yang, R., Nathan, S. S., Kolb, E. A., Mazza, B., Meyers, P. A., & Gorlick, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1952 · Cited by 261
Self-citationZeng, H., Chen, Z., Belinsky, M. G., Rea, P. A., & Kruh, G. D. (2001) · PubMed · Cited by 255
Role of endothelin-1 in osteoblastic bone metastases
Guise, T. A., Yin, J. J., & Mohammad, K. S. (2003) · Cancer · doi:10.1002/cncr.11129 · Cited by 228
Goorin, A. M., Harris, M. B., Bernstein, M. L., Ferguson, W., Devidas, M., Siegal, G. P., Gebhardt, M. C., Schwartz, C. L., Link, M. P., & Grier, H. E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.426 · Cited by 223
Rapamycin Inhibits Ezrin-Mediated Metastatic Behavior in a Murine Model of Osteosarcoma
Wan, X., Mendoza, A., Khanna, C., & Helman, L. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3135 · Cited by 216
An Expression Signature Classifies Chemotherapy-Resistant Pediatric Osteosarcoma
Mintz, M. B., Sowers, R., Brown, K. M., Hilmer, S. C., Mazza, B., Huvos, A. G., Meyers, P. A., LaFleur, B., McDonough, W. S., Henry, M. M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2463 · Cited by 215
Self-citationMRP Subfamily Transporters and Resistance to Anticancer Agents
Kruh, G. D., Zeng, H., Rea, P. A., Liu, G., Chen, Z.-S., Lee, K., & Belinsky, M. G. (2001) · Journal of Bioenergetics and Biomembranes · doi:10.1023/a:1012827221844 · Cited by 170
Ory, B., Heymann, M., Kamijo, A., Gouin, F., Heymann, D., & Redini, F. (2005) · Cancer · doi:10.1002/cncr.21530 · Cited by 169
Laverdière, C., Hoang, B. H., Yang, R. R., Sowers, R. S., Qin, J., Meyers, P. A., Huvos, A. G., Healey, J. H., & Gorlick, R. G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1089 · Cited by 168
Self-citationCapasso, L. L. (2005) · International Journal of Cancer · doi:10.1002/ijc.20610 · Cited by 161
Chu, F., Chou, P. M., Zheng, X., Mirkin, B. L., & Rebbaa, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2002 · Cited by 161
Vilella-Bach, M., Nuzzi, P., Fang, Y., & Chen, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.7.4266 · Cited by 154
Mechanisms of methotrexate resistance in osteosarcoma.
Guo, W., Healey, J. H., Meyers, P. A., Ladanyi, M., Huvos, A. G., Bertino, J. R., & Gorlick, R. G. (1999) · PubMed · Cited by 152
Self-citationHawkins, D. S., & Arndt, C. A. S. (2003) · Cancer · doi:10.1002/cncr.11799 · Cited by 147
Guo, W., Lonardo, F., Ueda, T., Kim, T. K., Huvos, A. G., Healey, J. H., & Ladanyi, M. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2<199::aid-ijc7>3.0.co;2-4 · Cited by 140
Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials
Alberts, D. S., Muggia, F. M., Carmichael, J., Winer, E. P., Jahanzeb, M., Venook, A. P., Skubitz, K. M., Rivera, E., Sparano, J. A., DiBella, N. J., et al. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.08.010 · Cited by 139
Bacci, G., Briccoli, A., Longhi, A., Ferrari, S., Mercuri, M., Faggioli, F., Versari, M., & Picci, P. (2005) · Acta Oncologica · doi:10.1080/02841860500327503 · Cited by 134
P-glycoprotein Expression: Critical Determinant in the Response to Osteosarcoma Chemotherapy
Chan, H. S. L., Haddad, G., DeBoer, G., Ling, V. W. T., & Grogan, T. M. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.22.1706 · Cited by 132
Chou, A. J., Merola, P. R., Wexler, L. H., Gorlick, R. G., Vyas, Y. M., Healey, J. H., LaQuaglia, M. P., Huvos, A. G., & Meyers, P. A. (2005) · Cancer · doi:10.1002/cncr.21417 · Cited by 131
Self-citationZhou, H., Randall, R. L., Brothman, A. R., Maxwell, T. M., Coffin, C. M., & Goldsby, R. E. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200301000-00007 · Cited by 125
Essential role of RSK2 in c-Fos–dependent osteosarcoma development
David, J., Mehic, D., Bakiri, L., Schilling, A. F., Mandic, V., Priemel, M., Idarraga, M. H., Reschke, M., Hoffmann, O., Amling, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22877 · Cited by 122
Evaluation of the role of RANK and OPG genes in Paget’s disease of bone
Wuyts, W. A., Wesenbeeck, L. V., Morales-Piga, A. A., Ralston, S. H., Hocking, L. J., Vanhoenacker, F. M. H. M., Westhovens, R., Verbruggen, L., Anderson, D. M., Hughes, A., et al. (2001) · Bone · doi:10.1016/s8756-3282(00)00411-7 · Cited by 121
IGF‐1 receptor contributes to the malignant phenotype in human and canine osteosarcoma
MacEwen, E. G., Pastor, J., Kutzke, J., Tsan, R. Z., Kurzman, I. D., Thamm, D. H., Wilson, M., & Radinsky, R. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20046 · Cited by 118
Alteration of pRb/p16/cdk4 regulation in human osteosarcoma
Benassi, M. S., Molendini, L., Gamberi, G., Ragazzini, P., Sollazzo, M. R., Merli, M., Asp, J., Magagnoli, G., Balladelli, A., Bertoni, F., et al. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991022)84:5<489::aid-ijc7>3.0.co;2-d · Cited by 115
McGary, E. C., WEBER, K. L., Mills, L., Doucet, M., Lewis, V., Lev, D. C., Fidler, I. J., & Bar‐Eli, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1101 · Cited by 113
CDKN2A Gene Deletions and Loss of p16 Expression Occur in Osteosarcomas That Lack RB Alterations
Nielsen, G. P., Burns, K. L., Rosenberg, A. E., & Louis, D. N. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65556-3 · Cited by 111
Li, W., Fan, J., Hochhauser, D., Banerjee, D., Zieliński, Z., Almasan, A., Yin, Y., Kelly, R., Wahl, G. M., & Bertino, J. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.22.10436 · Cited by 108
Pakos, E. E., & Ioannidis, J. P. A. (2003) · Cancer · doi:10.1002/cncr.11546 · Cited by 106
Purcell, W. T., & Ettinger, D. S. (2003) · Current Oncology Reports · doi:10.1007/s11912-003-0098-3 · Cited by 104
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma
Laverdière, C., Kolb, E. A., Supko, J. G., Gorlick, R. G., Meyers, P. A., Maki, R. G., Wexler, L. H., Demetri, G. D., Healey, J. H., Huvos, A. G., et al. (2003) · Cancer · doi:10.1002/cncr.11563 · Cited by 98
Self-citationMDR1 Gene Expression and Outcome in Osteosarcoma: A Prospective, Multicenter Study
Wunder, J. S., Bull, S. B., Aneliunas, V., Lee, P. D., Davis, A. M., Beauchamp, C. P., Conrad, E. U., Grimer, R. J., Healey, J. H., Rock, M. J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.14.2685 · Cited by 94
Itoh, K., Udagawa, N., Matsuzaki, K., Takami, M., Amano, H., Shinki, T., Ueno, Y., Takahashi, N., & Suda, T. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.9.1766 · Cited by 90
Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma
Coltella, N., Manara, M. C., Cerisano, V., Trusolino, L., Renzo, M. F. D., Scotlandi, K., & Ferracini, R. (2003) · The FASEB Journal · doi:10.1096/fj.02-0576fje · Cited by 85
Adjuvant chemotherapy of osteosarcoma.
Eilber, F. R., & Rosen, G. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.6.982 · Cited by 79
Anthracycline drug targeting: cytoplasmic versus nuclear – a fork in the road
Lothstein, L., Israel, M., & Sweatman, T. W. (2001) · Drug Resistance Updates · doi:10.1054/drup.2001.0201 · Cited by 76
Alendronate regulates cell invasion and MMP‐2 secretion in human osteosarcoma cell lines
Cheng, Y. Y., Huang, L., Lee, K., Li, K., & Kumta, S. M. (2004) · Pediatric Blood & Cancer · doi:10.1002/pbc.20019 · Cited by 60
Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples.
Yang, R. R., Sowers, R. S., Mazza, B., Healey, J. H., Huvos, A. G., Grier, H. E., Bernstein, M. L., Beardsley, G. P., Krailo, M., Devidas, M., et al. (2003) · PubMed · Cited by 57
Self-citationMansky, P. J., Liewehr, D. J., Steinberg, S. M., Chrousos, G. P., Avila, N. A., Long, L., Bernstein, D. B., Mackall, C. L., Hawkins, D. S., & Helman, L. J. (2002) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200208000-00007 · Cited by 56
Wittrant, Y., Lamoureux, F., Mori, K., Riet, A., Kamijo, A., Heymann, D., & Rédiní, F. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.1.261 · Cited by 54
Osteosarcomas and other cancers of bone
Bramwell, V. H. C. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200007000-00009 · Cited by 53
Sowers, R. S., Toguchida, J., Qin, J., Meyers, P. A., Healey, J. H., Huvos, A. G., Banerjee, D., Bertino, J. R., & Gorlick, R. G. (2003) · PubMed · Cited by 53
Self-citationReduced folate carrier protein expression in osteosarcoma
Ifergan, I., Meller, I., Isakov, J., & Assaraf, Y. G. (2003) · Cancer · doi:10.1002/cncr.11741 · Cited by 51
Modulation of Cisplatinum Cytotoxicity by p53: Effect of p53-Mediated Apoptosis and DNA Repair
Fan, J., & Bertino, J. R. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.5.966 · Cited by 51
Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma.
Serra, M., Maurici, D., Scotlandi, K., Bròdano, G. B., Manara, M. C., Benini, S., Picci, P., Bertoni, F., Bacci, G., Sottili, S., et al. (1999) · International Journal of Oncology · doi:10.3892/ijo.14.2.301 · Cited by 43
Miyamoto, N., Higuchi, Y., Mori, K., Ito, M., Tsurudome, M., Nishio, M., Yamada, H., Sudo, A., Kato, K., Uchida, A., et al. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(01)00134-5 · Cited by 43
The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (Review)
Kim, R., Tanabe, K., Uchida, Y., Osaki, A., & Toge, T. (2002) · Oncology Reports · doi:10.3892/or.9.1.3 · Cited by 40
Fukaya, Y., Ishiguro, N., Senga, T., Ichigotani, Y., Sohara, Y., Motomu, T., Shioura, T., Iwamoto, T., & Hamaguchi, M. (2005) · Oncology Reports · doi:10.3892/or.14.4.847 · Cited by 40
Molecular mechanisms of bone metastasis and therapeutic implications.
O'Keefe, R., & Guise, T. (2003) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000093847.72468.2f · Cited by 34
Osteosarcoma Necrosis Following Chemotherapy: Innate Biology Versus Treatment-Specific
Gorlick, R. G., & Meyers, P. A. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200311000-00003 · Cited by 33
Self-citationAshton, J. A., Farese, J. P., Milner, R. J., Lee-Ambrose, L. M., & Gilder, J. M. V. (2005) · American Journal of Veterinary Research · doi:10.2460/ajvr.2005.66.885 · Cited by 29
Pratt, C. B., Epelman, S., & Jaffe, N. (1987) · PubMed · Cited by 25
Advances that are changing the diagnosis and treatment of malignant bone tumors
Casas-Ganem, J. E., & Healey, J. H. (2004) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000146608.03927.16 · Cited by 20
Cited by
Osteosarcoma treatment – Where do we stand? A state of the art review
Luetke, A., Meyers, P. A., Lewis, I., & Juergens, H. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.11.006 · Cited by 1,234
Lilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 283
Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers
Avril, T., Vauléon, E., & Chevet, E. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.72 · Cited by 277
Therapy for Osteosarcoma: Where Do We Go From Here?
Chou, A. J., Geller, D. S., & Gorlick, R. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810050-00005 · Cited by 274
Self-citationTu, B., Zhu, J., Liu, S., Wang, L., Fan, Q., Hao, Y., Fan, C., & Tang, T.-T. (2016) · Oncotarget · doi:10.18632/oncotarget.10219 · Cited by 95
Metadata
- Authors
- Chou, A. J., & Gorlick, R.
- Venue
- Expert Review of Anticancer Therapy
- Publisher
- Informa UK Limited
- Published
- 2006-07
- Volume
- 6
- Issue
- 7
- Pages
- 1075-1085
- ISSN
- 1473-7140 (ISSN-L)
- 1744-8328
- OpenAlex
- W2131112855
- Cited by
- 377
- References
- 74
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.